Literature DB >> 19929586

Management of stress in inflammatory bowel disease: a therapeutic option?

James R Goodhand1, Mahmood Wahed, David S Rampton.   

Abstract

There is increasing evidence that psychological stress and associated mood disorders are linked with, and can adversely affect the course of, inflammatory bowel disease (IBD). Unfortunately, owing to methodological difficulties inherent in undertaking appropriately targeted and blinded trials, there are limited high-quality data regarding the effects on IBD of interventions aimed to ameliorate stress and mood disorders. Nevertheless, patients want psychological intervention as well as conventional medical strategies. Emerging trial evidence supports the suggestion that psychologically orientated therapy may ameliorate IBD-associated mood disorders, but there are no strong data as of yet to indicate that stress management has a beneficial effect on the activity or course of IBD. As yet, which, when and how interventions targeted at psychological stress and mood disturbances should be offered to individual patients with IBD is not clear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19929586     DOI: 10.1586/egh.09.55

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  13 in total

Review 1.  Epidemiology and risk factors for IBD.

Authors:  Ashwin N Ananthakrishnan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-03       Impact factor: 46.802

2.  Pharmacy-led switches of 5-ASA: impact on secondary care.

Authors:  Chris J Healey; John O'Malley
Journal:  Frontline Gastroenterol       Date:  2012-11-12

3.  Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms.

Authors:  Rachel D Thompson; Anna Craig; Emily A Crawford; Diane Fairclough; Joseph Gonzalez-Heydrich; Athos Bousvaros; Robert B Noll; David R DeMaso; Eva Szigethy
Journal:  J Clin Psychol Med Settings       Date:  2012-09

Review 4.  Modifiable Environmental Factors in Inflammatory Bowel Disease.

Authors:  Kristin E Burke; Christine Boumitri; Ashwin N Ananthakrishnan
Journal:  Curr Gastroenterol Rep       Date:  2017-05

5.  Psychological interventions for inflammatory bowel disease: a systematic review and component network meta-analysis protocol.

Authors:  Natalia Tiles-Sar; Johanna Neuser; Dominik de Sordi; Gerta Rücker; Anne Baltes; Jan Preiss; Gabriele Moser; Antje Timmer
Journal:  BMJ Open       Date:  2022-06-22       Impact factor: 3.006

6.  Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease.

Authors:  David Benhayon; Ada Youk; F Nicole McCarthy; Stephanie Davis; David J Keljo; Athos Bousvaros; Diane Fairclough; David Kupfer; Daniel J Buysse; Eva M Szigethy
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-09       Impact factor: 2.839

7.  Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease.

Authors:  A N Ananthakrishnan; V S Gainer; R G Perez; T Cai; S-C Cheng; G Savova; P Chen; P Szolovits; Z Xia; P L De Jager; S Y Shaw; S Churchill; E W Karlson; I Kohane; R H Perlis; R M Plenge; S N Murphy; K P Liao
Journal:  Aliment Pharmacol Ther       Date:  2013-01-07       Impact factor: 8.171

8.  The specialized educational and psychological counseling in inflammatory bowel disease patients - a target or a challenge?

Authors:  Otilia Gavrilescu; Cristina Cijevschi Prelipcean; Mihaela Dranga; Camelia Soponaru; Catalina Mihai
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

9.  Modeling autism: a systems biology approach.

Authors:  Mary Randolph-Gips; Pramila Srinivasan
Journal:  J Clin Bioinforma       Date:  2012-10-08

10.  Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial.

Authors:  Mariyana Schoultz; Iain Atherton; Angus Watson
Journal:  Trials       Date:  2015-08-25       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.